Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines

Human Vaccines

Volumn 6, Issue 4, 2010, Pages 355-359

  Liu, Jun ^a   Ostrowski, Mario ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Adjuvant; ALVAC; CD40L (CD154); Human immunodeficiency virus (HIV); OX40L (CD252); Tumor necrosis factor superfamily (TNFSF); Vaccine

Indexed keywords

ADJUVANT; ALVAC HIV 1 VACCINE; B CELL ACTIVATING FACTOR RECEPTOR; CD40 LIGAND; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; OSTEOCLAST DIFFERENTIATION FACTOR; OX40 LIGAND; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOREGULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NOTE; THAILAND; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; MICE; MODELS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953627253     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.4.10867     Document Type: Note

References (39)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:17-9.
2. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009.
4. Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009; 27:5077-84.
5. Liu J, Yu Q, Stone GW, Yue FY, Ngai N, Jones RB, et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008; 26:4062-72.
6. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27:19-26.
7. Collette Y, Gilles A, Pontarotti P, Olive D. A coevolution perspective of the TNFSF and TNFRSF families in the immune system. Trends Immunol 2003; 24:387-94.
8. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501. (Pubitemid 32201945)
9. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68. (Pubitemid 40563164)
10. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271-85.
11. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22:307-28.
12. Bishop GA, Hostager BS. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 2003; 14:297-309.
13. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009; 229:173-91.
14. Stuber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996; 183:979-89.
15. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, Ecabert B, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 1999; 11:699-708. (Pubitemid 30030709)
16. Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006; 24:3399-407.
17. Cox WI, Tartaglia J, Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993; 195:845-50. (Pubitemid 23226216)
18. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188:217-32.
19. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995; 13:539-49.
20. de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704-13.
21. Yu Q, Jones B, Hu N, Chang H, Ahmad S, Liu J, et al. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 2006; 24:6376-91.
22. Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVACHIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 2007; 46:222-30.
23. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192:1249-59.
24. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48-55. (Pubitemid 47507433)
25. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-17.
26. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002; 20:7-12.
27. + T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 2003; 170:1797-805.
28. + T regulatory cell inhibition. J Immunol 2006; 176:2486-95.
29. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006; 80:1762-72.
30. Fang ZY, Limbach K, Tartaglia J, Hammonds J, Chen X, Spearman P. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 2001; 291:272-84.
31. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985; 313:79-84.
32. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-9.
33. Melchers M. Enhancing the immunogenicity of HIV-1 envelope glycoprotein trimers by fusion to CD40 ligand. AIDS Vaccine 2008; 2008 Oct 13-16; Cape Town, South Africa; 2008.
34. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18:263-75.
35. Serghides L, Bukczynski J, Wen T, Wang C, Routy JP, Boulassel MR, et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol 2005; 175:6368-77.
36. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation and tissue destruction. J Immunol 2001; 167:6330-7.
37. Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15:801-12.
38. Zhu G, Flies DB, Tamada K, Sun Y, Rodriguez M, Fu YX, et al. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha- transgenic mice. J Immunol 2001; 167:2671-6.
39. Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, Yamamoto N. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 2001; 75:6748-57.